Industry news that matters to you.  Learn more

Archives for April 2016

Imbio and GE Healthcare Collaborate to Enable Lung Density Analysis Within GE Health Cloud Ecosystem

Imbio, a leader in fully automated, biomarker-based solutions for quantitative Lung imaging, and GE Healthcare are pleased to announce a collaboration to make Imbio’s Lung Density Analysis™, a volumetric imaging solution for Lung CT, one of the first software applications to be available in the GE Health Cloud.

N-of-One Selected by Admera Health to Provide Clinical Interpretation for the OncoGxOne 64-Gene Oncology Panel

N-of-One, Inc., the leader in clinical interpretation of molecular tests in oncology, recently announced that Admera Health, a molecular diagnostics company focused on personalized medicine and non-invasive cancer testing, has selected N-of-One to provide clinical interpretation of their 64-gene oncology panel, OncoGxOne™. N-of-One’s patient-specific analysis is based on the clinical and scientific evidence linking the results of each patient’s molecular tests to therapeutic strategies, including clinical trials. Financial terms of the agreement are not disclosed.

QIAGEN Partners with IT leaders on Novel Infrastructure for Genomics

QIAGEN N.V. recently announced it will demonstrate the result of its work with information technology leaders Intel and BioTeam at Bio-IT World. Together these collaborations create infrastructure solutions that make population-scale genomic analysis feasible for more researchers. QIAGEN Bioinformatics has worked with Intel to develop a computational solution and reference architecture for whole genome analysis, and with BioTeam to create a proof-of-concept high-performance computing (HPC) appliance. QIAGEN is demonstrating both of these solutions at the Bio-IT World Conference and Expo from April 5-7 in Boston.

200 Million Americans Now Have Insurance Coverage for Biodesix’s VeriStrat Test; BCBS of FLorida and Health Services Corporation Issue Positive Coverage Decisions

VeriStrat®, Biodesix’ proteomic blood test for patients with advanced NSCLC, has received multiple positive coverage decisions in 2016. As a result, 200 million Americans now have insurance coverage for VeriStrat. The most recent positive coverage decisions include BlueCross BlueShield (BCBS) of Florida and Health Care Services Corporation (HCSC).

DiaSorin To Acquire Focus Diagnostics’ Molecular And Immunoassay Product Business From Quest Diagnostics, Significantly Advancing Its Presence In The Molecular Diagnostic Market

DiaSorin S.p.A. (F TSE Italy: DIA) and Quest Diagnostics (NYSE: DGX) recently announced that they have entered into a purchase agreement under which DiaSorin will buy Quest’s Focus Diagnostics, Inc. immunodiagnostic and molecular diagnostic products business (“Focus”).